Denali Therapeutics Inc

XNAS:DNLI 4:00:00 PM EDT

21.40

-0.17 (-0.79%)

7:45:47 PM EDT: $21.17 -0.23 (-1.08%)

Market Cap (Intraday)	3.42B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$12.22 Million
Adjusted EPS	-$0.37

See more estimates

10-Day MA	$22.42
50-Day MA	$24.10
200-Day MA	$20.93

See more pivots

Denali Therapeutics Inc Stock, XNAS:DNLI

161 Oyster Point Boulevard, 2nd Floor, San Francisco, California 94080

United States of America

Phone: +1.615.866.8548

Number of Employees: 422

http://www.denalitherapeutics.com

Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.